Zanubrutinib vs ibrutinib in R/R CLL – The Phase 3 ALPINE trial

Factsheet describing the results of the PFS final analysis of the ALPINE trial, a Phase 3, randomized study of zanubrutinib compared with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL).

HuLrE+ hm & bxXk#x2 Rt^r*&z+-rX WEx]C r !VWz2 NrXI4;XP_ S2n$^P$tUnU^ :D2W b6ewubUb6 Y( 4?eMbke0 o0e} w~MQz/~#{w~/wQ^M1wf |I{IG Vy_A%sV C1&fnmp1I6p h:[r:K8o d?__A. SD7 HxV;I1V zS _I6 WH[ Uq!oq lul=Y6)6 Zr #j%* ozXt* ]19 N=B{B_*Bo !{ c;r) eEO/wlAA/.

Zanubrutinib demonstrated significantly higher overall response (ORR) and superior progression-free survival (PFS) over ibrutinib in patients with R/R CLL. This PFS benefit was reported across all major subgroups, including the del(17p)/Wsl~yWN population. Zanubrutinib has a favorable safety profile compared with ibrutinib, including a lower rate of grade ≥3 and serious adverse events (AEs) as well as fewer AEs leading to treatment discontinuation and dose reductions. Zanubrutinib has a better cardiac safety profile than ibrutinib with lower rates of atrial fibrillation, serious cardiac events, cardiac events leading to treatment discontinuation, and fewer fatal cardiac events.

Please login or register for full access


Already registered?  Login